Ivermectin has beneficial effects against SARS-COV-2

Ivermectin has beneficial effects against SARS-COV-2 is a claim based on 76 independent studies conducted by researchers around the world. These studies show an unambiguous medical benefit for treatment with Ivermectin in patients suffering from SARS-COV-2 infection and Covid-19 disease.

Reasons & Support

Statistically significant improvements are seen for mortality, ventilation, ICU admission, hospitalization, recovery, cases, and viral clearance. All remain significant after exclusions. 49 studies from 45 independent teams in 21 different countries show statistically significant improvements in isolation (37 primary outcome, 34 most serious outcome). Meta analysis using the most serious outcome shows 66% [53‑75%] and 83% [74‑89%] improvement for early treatment and prophylaxis, with similar results after exclusion based sensitivity analysis (excluding all GMK/BBC team studies), for primary outcomes, for peer-reviewed studies, and for RCTs. Results are very robust — in worst case exclusion sensitivity analysis 60 of 76 studies must be excluded to avoid finding statistically significant efficacy.

Results	Studies	Prophylaxis	Early treatment	Late treatment	Patients	Authors
All studies	76	83% [74‑89%]	66% [53‑75%]	39% [23‑52%]	57,647	718
Peer-reviewed	55	83% [73‑90%]	68% [50‑80%]	41% [17‑58%]	25,228	558
With GMK/BBC exclusions	51	82% [68‑89%]	73% [64‑80%]	53% [29‑69%]	44,741	545
Randomized Controlled Trials	32	84% [25‑96%]	62% [45‑74%]	23% [-1‑41%]	7,032	361
RCTs w/GMK/BBC exclusions	25	84% [25‑96%]	69% [56‑77%]	26% [-2‑46%]	4,423	299
Percentage improvement with ivermectin treatment in bold (confidence interval in brackets)

Claim

Statement of the claim	Ivermectin has beneficial effects against SARS-COV-2
Level of certainty	True
Nature	Factual
Counterclaim	Ivermectin has no effect or detrimental effects against SARS-COV-2
Dependent on	Definition:SARS-COV-2
Dependency of

References

ivmmeta.com